Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75


T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.

Laurent J, Touvrey C, Gillessen S, Joffraud M, Vicari M, Bertrand C, Ongarello S, Liedert B, Gallerani E, Beck J, Omlin A, Sessa C, Quaratino S, Stupp R, Gnad-Vogt US, Speiser DE.

J Transl Med. 2013 Jan 7;11:5. doi: 10.1186/1479-5876-11-5.


A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.

Gillessen S, Gnad-Vogt US, Gallerani E, Beck J, Sessa C, Omlin A, Mattiacci MR, Liedert B, Kramer D, Laurent J, Speiser DE, Stupp R.

Eur J Cancer. 2013 Jan;49(1):35-44. doi: 10.1016/j.ejca.2012.07.015. Epub 2012 Aug 20.


A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity.

Gillies SD, Lan Y, Hettmann T, Brunkhorst B, Sun Y, Mueller SO, Lo KM.

Clin Cancer Res. 2011 Jun 1;17(11):3673-85. doi: 10.1158/1078-0432.CCR-10-2921. Epub 2011 Apr 29.


IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.

Wu Z, Xu Y.

J Mol Cell Biol. 2010 Aug;2(4):217-22. doi: 10.1093/jmcb/mjq012.


Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.

Varker KA, Kondadasula SV, Go MR, Lesinski GB, Ghosh-Berkebile R, Lehman A, Monk JP, Olencki T, Kendra K, Carson WE 3rd.

Clin Cancer Res. 2006 Oct 1;12(19):5850-8.


Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.

Camisaschi C, Filipazzi P, Tazzari M, Casati C, Beretta V, Pilla L, Patuzzo R, Maurichi A, Cova A, Maio M, Chiarion-Sileni V, Tragni G, Santinami M, Vergani B, Villa A, Berti E, Umansky L, Beckhove P, Umansky V, Parmiani G, Rivoltini L, Castelli C.

Cancer Immunol Immunother. 2013 May;62(5):897-908. doi: 10.1007/s00262-013-1397-7. Epub 2013 Apr 16.


Phase-II randomized study of pre-operative IL-2 administration in operable NSCLC.

Masotti A, Morandini G, Ortolani R, Fumagalli L.

Lung Cancer. 1998 Jun;20(3):191-202.


Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.

de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.

Clin Cancer Res. 2000 Apr;6(4):1267-72.


Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.

Nichols J, Foss F, Kuzel TM, LeMaistre CF, Platanias L, Ratain MJ, Rook A, Saleh M, Schwartz G.

Eur J Cancer. 1997 Jan;33 Suppl 1:S34-6. Review.


[Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].

Chi PD, Li L, Fan YY, Wu CY.

Ai Zheng. 2007 Aug;26(8):801-8. Chinese.


NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.

Salagianni M, Lekka E, Moustaki A, Iliopoulou EG, Baxevanis CN, Papamichail M, Perez SA.

J Immunol. 2011 Mar 15;186(6):3327-35. doi: 10.4049/jimmunol.1000652. Epub 2011 Feb 11.


Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis.

Cesana GC, Romano F, Piacentini G, Scotti M, Brenna A, Bovo G, Vaghi M, Aletti G, Caprotti R, Kaufman H, Uggeri F.

Ann Surg Oncol. 2007 Apr;14(4):1295-304. Epub 2007 Jan 17.


Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.

Lode HN, Xiang R, Duncan SR, Theofilopoulos AN, Gillies SD, Reisfeld RA.

Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8591-6.


Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.

Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL.

J Clin Oncol. 2006 Mar 1;24(7):1169-77.


A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.

Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3562-70.


Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.

de Vries IJ, Castelli C, Huygens C, Jacobs JF, Stockis J, Schuler-Thurner B, Adema GJ, Punt CJ, Rivoltini L, Schuler G, Coulie PG, Lucas S.

Clin Cancer Res. 2011 Feb 15;17(4):841-8. doi: 10.1158/1078-0432.CCR-10-2227. Epub 2010 Dec 21.


An interleukin-2-IgG-Fas ligand fusion protein suppresses delayed-type hypersensitivity in mice by triggering apoptosis in activated T cells as a novel strategy for immunosuppression.

Bulfone-Paus S, Rückert R, Krause H, von Bernuth H, Notter M, Pohl T, Tran TH, Paus R, Kunzendorf U.

Transplantation. 2000 Apr 15;69(7):1386-91. Retraction in: Transplantation. 2011 Dec 27;92(12):e68.


Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.

Nagamine I, Yamaguchi Y, Ohara M, Ikeda T, Okada M.

Hiroshima J Med Sci. 2009 Mar;58(1):37-44.


[Interferon therapy effects on activation of T-lymphocytes in patients with systemic lupus erythematosus].

Stanislav ML, Balabanova RM, Nikonova MF, Litvina MM, Iarilin AA.

Ter Arkh. 2000;72(5):44-9. Russian.


Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.

Robertson MJ, Cameron C, Atkins MB, Gordon MS, Lotze MT, Sherman ML, Ritz J.

Clin Cancer Res. 1999 Jan;5(1):9-16.

Supplemental Content

Support Center